Lixte Biotechnology Holdings, Inc. (LIXT) Financial Statements
Industry: Pharmaceutical Preparations
Net income was -$6.1M, or -$1.26 per diluted share. Operating activities generated -$3.1M of cash. At fiscal year end, Lixte Biotechnology held $12.7M in total assets against $1.8M in total liabilities.
Open the full interactive Lixte Biotechnology financials → Quarterly statements, key ratios, valuation history and price charts.
Lixte Biotechnology Key Stats
| Share Price | $4.28 |
|---|---|
| Market Cap | $57.7M |
| 52-Week Range | $2.44 – $8.04 |
| Shares Outstanding | 13.5 million (basic, 2026 Q2) |
Lixte Biotechnology Income Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Operating Income | -$3.3M | -$6.7M | -$6.3M | -$5.1M | -$3.6M | -$5.1M |
| Pre-Tax Income | -$3.3M | -$6.7M | -$6.3M | -$5.1M | -$3.6M | -$6.1M |
| Income Tax | — | — | — | — | — | $1,600 |
| Net Income | -$3.3M | -$6.7M | -$6.3M | -$5.1M | -$3.6M | -$6.1M |
| Diluted EPS | -$2.90 | -$5.00 | — | -$2.66 | -$1.59 | -$1.26 |
Lixte Biotechnology Quarterly Results
| 2025 Q3 | 2025 Q4 | 2026 Q1 | 2026 Q2 | |
|---|---|---|---|---|
| Net Income | -$2.0M | -$2.6M | -$1.9M | -$2.2M |
| Diluted EPS | -$0.33 | -$0.54 | -$0.18 | -$0.16 |
Lixte Biotechnology Balance Sheet
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $5.1M | $4.8M | $5.4M | $4.2M | — | — |
| Current Assets | $5.2M | $5.1M | $5.6M | $4.3M | — | $5.2M |
| Total Assets | $5.2M | $5.1M | $5.6M | $4.3M | $1.1M | $12.7M |
| Current Liabilities | $216,524 | $302,926 | $394,786 | $313,858 | $318,284 | $1.3M |
| Total Liabilities | $216,524 | $302,926 | $394,786 | $313,858 | $318,284 | $1.8M |
| Shareholders' Equity | $5.0M | $4.8M | $5.2M | $4.0M | $827,219 | $9.7M |
Lixte Biotechnology Cash Flow Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash From Operations | $2.1M | -$4.1M | -$4.6M | -$4.3M | -$3.2M | -$3.1M |
| Cash From Investing | — | — | — | — | — | -$3.2M |
| Cash From Financing | $4.6M | $3.9M | $5.1M | $3.1M | — | $10.3M |
Figures from Lixte Biotechnology's 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full Lixte Biotechnology financials page for every line item.
Lixte Biotechnology Company Profile
| Ticker | LIXT |
|---|---|
| Exchange | Nasdaq |
| Industry | Pharmaceutical Preparations |
| Headquarters | Boca Raton, Florida |
| Incorporated in | Delaware |
| Fiscal Year End | December 31 |
| SEC Filer Category | Non-accelerated filer, smaller reporting company |
| SEC CIK | 0001335105 |
Frequently Asked Questions
What was Lixte Biotechnology's net income in fiscal 2025?
Lixte Biotechnology reported net income of -$6.1M for fiscal 2025.
What was Lixte Biotechnology's earnings per share (EPS) in fiscal 2025?
Lixte Biotechnology's diluted EPS was -$1.26 for fiscal 2025 (adjusted for any later stock splits).
How many shares of Lixte Biotechnology are outstanding?
Lixte Biotechnology reported a weighted average of 13.5 million basic shares outstanding in 2026 Q2.
What is Lixte Biotechnology's market cap?
Based on its latest closing price, Lixte Biotechnology (LIXT) has a market capitalization of about $57.7M.
When does Lixte Biotechnology's fiscal year end?
Lixte Biotechnology's fiscal year end, as registered with the SEC, is December 31.
Where is Lixte Biotechnology headquartered?
Lixte Biotechnology lists its business address in Boca Raton, Florida in its SEC filings.